Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa

doi:10.1007/s10147-013-0554-5

Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

Naohiro Watanabe
, Hiroyuki Taniguchi
, Yasuhiro Kondoh
, Tomoki Kimura
, Kensuke Kataoka
, Osamu Nishiyama
, Masashi Kondo
, Yoshinori Hasegawa

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

Original language	English
Pages (from-to)	260-265
Number of pages	6
Journal	International Journal of Clinical Oncology
Volume	19
Issue number	2
DOIs	https://doi.org/10.1007/s10147-013-0554-5
Publication status	Published - 04-2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Surgery
Hematology
Oncology

Access to Document

10.1007/s10147-013-0554-5

Cite this

@article{2ef4dd88838d484188cc8b86b5fe3826,

title = "Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis",

abstract = "Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 \%. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.",

author = "Naohiro Watanabe and Hiroyuki Taniguchi and Yasuhiro Kondoh and Tomoki Kimura and Kensuke Kataoka and Osamu Nishiyama and Masashi Kondo and Yoshinori Hasegawa",

note = "Funding Information: This study was partly supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan. ",

year = "2014",

month = apr,

doi = "10.1007/s10147-013-0554-5",

language = "English",

volume = "19",

pages = "260--265",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

AU - Watanabe, Naohiro

AU - Taniguchi, Hiroyuki

AU - Kondoh, Yasuhiro

AU - Kimura, Tomoki

AU - Kataoka, Kensuke

AU - Nishiyama, Osamu

AU - Kondo, Masashi

AU - Hasegawa, Yoshinori

N1 - Funding Information: This study was partly supported by a grant to the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan.

PY - 2014/4

Y1 - 2014/4

N2 - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

AB - Background: Idiopathic pulmonary fibrosis (IPF) is associated with an independent increased risk of lung carcinogenesis. The benefit of chemotherapy for extensive-stage small-cell lung cancer (ED-SCLC) in cases of IPF remains unknown. This study was conducted to elucidate the efficacy of chemotherapy for ED-SCLC in patients with IPF. Methods: This was a retrospective observational study of ED-SCLC patients with IPF (all with distant metastasis) who received systemic chemotherapy. The response rate, toxicity, overall survival, and progression-free survival (PFS) were investigated. Results: Eleven patients treated with chemotherapy between January 2005 and December 2011 were the subjects of this study. The overall response rate with the 1st regimen was 63.6 %. The median overall survival was 7.0 months, and the median PFS was 4.7 months. Conclusion: Our results suggest that ED-SCLC patients with IPF may benefit from chemotherapy. A prospective study will be needed to confirm this in the future.

UR - https://www.scopus.com/pages/publications/84899988574

UR - https://www.scopus.com/pages/publications/84899988574#tab=citedBy

U2 - 10.1007/s10147-013-0554-5

DO - 10.1007/s10147-013-0554-5

M3 - Article

C2 - 23592279

AN - SCOPUS:84899988574

SN - 1341-9625

VL - 19

SP - 260

EP - 265

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 2

ER -

Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this